What Sunstone Life Science Ventures does

Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007 and headquartered in Frederiksberg, Denmark. The firm specializes in early-stage investments in life science companies developing novel therapeutics for humans, deploying capital across pre-clinical through Phase 3 clinical development stages. Sunstone originated as one of two investment arms of Sunstone Capital and became a standalone entity in February 2019 when it was spun off alongside Heartcore Capital. The firm operates through a series of alternative investment funds (Fund II, Fund III, Fund IV), with Fund IV achieving a first close at €80 million in February 2019. The firm is supported by InnovFin Equity with financial backing from the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI), and is a member of Invest Europe, DVCA, and Active Owners Denmark.

Sunstone's business model follows the standard European VC fund manager structure: it earns recurring management fees on capital under management across its fund vintages and is eligible for carried interest on successful portfolio exits. The firm serves two distinct customer constituencies — early-stage life science therapeutics companies (which receive capital, scientific and strategic support, and network access through a dedicated Business Development Advisory Board) and institutional Limited Partners (LPs) such as Novo Holdings A/S who commit capital to the funds. Deal flow is driven by a screening engine that reviews 400–500 investment opportunities per year, with submissions funneled through a website-based project portal alongside network-sourced deals. The investment process uses a standardized investment proposal format and typically takes 4–6 weeks for initial assessment.

Since inception, Sunstone has contributed to bringing multiple new drugs to market and supported companies whose therapies account for over 20 life-changing products approved for treatment or diagnosis of patients. The portfolio spans CNS disorders (Synendos, Kynexis), neurodegeneration (Teitur Trophics), oncology (IO Biotech, Stipe Therapeutics), anti-infectives (MinervaX, F2G), cardiac disease (Cardior), rare disease (Orphazyme), and women's health (Forendo Pharma). Notable exits include the 2024 acquisition of Cardior Pharmaceuticals by Novo Nordisk and the 2019 sale of Nuevolution to Amgen at SEK 332 per share (SEK 332M total). The team is led by Managing General Partner Søren Lemonius, Chairman & General Partner Peter Benson, General Partner Claus Andersson, Investment Director Jacob Lange Moresco, and Venture Partners Sten Verland (co-founder, part-time since February 2024) and Hans T. Schambye (since February 2025).

Name

Sunstone Life Science Ventures

Legal name

Sunstone Life Science Ventures A/S

Website

https://sunstone.eu

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007 that invests in early-stage life science companies developing novel therapeutics for humans, managing multiple funds including a €80M Fund IV and contributing to over 20 approved therapeutic products.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital investing
• Life science therapeutics
• Early-stage biotech funding
• Alternative investment funds
• Biopharmaceutical venture capital

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management Fees: Sunstone manages multiple alternative investment funds and generates revenue through management fees charged on funds under management.
2. Carried Interest: Performance-based carried interest from successful portfolio exits, typical VC fund structure where managers receive a share of profits above a defined return threshold.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Sunstone Life Science Ventures is an independent European venture capital investment firm that manages a series of alternative investment funds (Fund II, Fund III, Fund IV) investing in early-stage life science companies developing novel therapeutics for humans. The firm sources, evaluates, and provides equity capital and strategic support to biotech companies across pre-clinical through Phase 3 clinical stages, targeting returns through portfolio company exits while charging management fees to limited partners.

Product overview

Sunstone Life Science Ventures is an independent European venture capital investment firm that manages a series of alternative investment funds (Fund II, Fund III, and Fund IV). The firm's purpose is to seek out, enable and empower the most promising life science therapeutics innovations, turning new science into new products that improve outcomes for patients. The funds invest in early-stage life science companies developing novel therapeutics for humans, supporting companies through pre-clinical to clinical phase 3 studies, and have contributed to bringing several new drugs into the market since inception in 2007.

Differentiator

Problem solved

Functional benefit

Products and services

• Sunstone Life Science Ventures Fund II K/S Second generation venture capital fund managed by Sunstone Life Science Ventures, investing in early-stage life science companies developing novel therapeutics for humans. Available to qualified institutional limited partner investors.
• Sunstone Life Science Ventures Fund III K/S Third generation venture capital fund managed by Sunstone Life Science Ventures, investing in early-stage life science companies developing novel therapeutics for humans. Available to qualified institutional limited partner investors.
• Sunstone Life Science Ventures Fund IV K/S Fourth generation venture capital fund managed by Sunstone Life Science Ventures with a first close of €80 million in February 2019. Invests in early-stage life science companies developing novel therapeutics for humans. Novo Holdings A/S joined as a Limited Partner in October 2020.

Quantifiable outcome

• 20 life-changing products approved for treatment or diagnosis
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Invest EuropecoreOthersSunstone is a member of Invest Europe and complies with their Reporting Guidelines and International Private Equity and Venture Capital Valuation Guidelines. Member organizations include DVCA and IE3.
• Active Owners DenmarkminorOthersSunstone is a member of Active Owners Denmark and complies with their Tax Code of Conduct for Investing members.
• DANISH BIO – DANSK BIOTEKcoreStrategic or Co-development PartnerSunstone collaborated with DANISH BIO – DANSK BIOTEK to analyze and quantify the Series A financing landscape in Denmark, studying the actual need for Series A funding in the Danish biotech ecosystem.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• HealthCap: Nordic and European life sciences venture capital firm investing in breakthrough therapeutics. Highly comparable in geography, sector focus, and early-to-growth stage investment approach.
• Wellington Partners: European venture capital firm investing across technology and life sciences. Comparable as co-investor in Sunstone-backed companies (e.g., MinervaX) with overlapping European biotech portfolio.
• Ysios Capital: Spanish venture capital firm specialized in life sciences, investing in therapeutics and diagnostics across Europe. Comparable early-to-mid stage biotech strategy with European geographic coverage.
• Forbion: Leading European life sciences venture capital firm managing multiple funds focused on innovative therapeutics. Comparable strategy of investing in early-to-mid-stage biotech with similar geographic European footprint.
• Industrifonden: Swedish venture capital investor with a significant life sciences franchise. Comparable Nordic geography and life sciences therapeutics investment mandate, often co-investing with Sunstone.
• BB Pureos Bioventures: Swiss-based venture capital firm focused on early-stage biotech therapeutics. Comparable early-stage European biotech focus and fund size profile.
• Hadean Ventures: Nordic life science venture capital firm investing in therapeutics and medical technology. Comparable Nordic focus, fund size, and early-stage biotech investment approach.
• Novo Seeds: Seed and early-stage life science venture arm of Novo Holdings A/S, based in Denmark. Direct competitor for Nordic biotech deal flow and co-LP in Sunstone's Fund IV, making it the closest comparable.
• EQT Life Sciences (formerly LSP): European-dedicated healthcare and life sciences venture capital firm within the EQT platform. Direct peer in funding innovative therapeutics with substantially larger fund sizes.
• Sofinnova Partners: Leading European venture capital firm with a long-standing life sciences strategy investing across biotech and medtech stages. Comparable as one of Europe's longest-tenured healthcare-focused VCs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xdk.linkedin.com/company/sunstone-life-science-ventures
• LinkedInlinkedin.com/company/sunstone-life-science-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments63 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sunstone Life Science Ventures